Status:

COMPLETED

Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis

Lead Sponsor:

Amgen

Conditions:

Anaemia

Chronic Kidney Disease (CKD)

Eligibility:

All Genders

18-100 years

Brief Summary

To describe anaemia correction via haemoglobin measurements taken throughout observation period in ESA naive patients with chronic kidney disease initiated on darbepoetin alfa QM

Detailed Description

Darbepoetin alfa (Aranesp) is a long-acting ESA approved for treatment of anaemia in CKD patients, and may be administered once a week (QW), once every two weeks (Q2W) or once a month (QM) for correct...

Eligibility Criteria

Inclusion

  • Patients ≥18 years of age.
  • Patients with CKD:
  • Not on dialysis at time of darbepoetin alfa initiation at QM dosing frequency.
  • Hb \<10g/dL immediately prior to initiation of darbepoetin alfa at QM dosing.
  • Commenced darbepoetin alfa at QM dosing frequency during or after August 2013.
  • Received at least three consecutive doses of darbepoetin alfa at QM dosing frequency, being the initiation dose and two further doses at QM dosing frequency.
  • Patient or patient's legally acceptable representative has provided informed consent, if applicable according to local requirements.

Exclusion

  • Treatment with an ESA within 14 weeks prior to initiation of darbepoetin alfa.
  • Patient was enrolled in an interventional device or drug study at any time during the 46-week data observation period or within 30 days prior to commencement of the data observtion period.

Key Trial Info

Start Date :

June 1 2014

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

April 1 2015

Estimated Enrollment :

308 Patients enrolled

Trial Details

Trial ID

NCT02185911

Start Date

June 1 2014

End Date

April 1 2015

Last Update

March 8 2016

Active Locations (40)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 10 (40 locations)

1

Research Site

Feldkirch, Austria, 6807

2

Research Site

Linz, Austria, 4020

3

Research Site

Vienna, Austria, 1220

4

Research Site

Dobrich, Bulgaria, 9300